ストックスクリーナーアプリを入手
0.8801
5.37%
-0.0499
アフターアワーズ：
.89
0.0099
+1.12%
前日終値:
$0.93
開ける：
$0.96
24時間の取引高:
135.99K
Relative Volume:
0.07
時価総額：
$3.83M
収益：
$1.31M
当期純損益:
$-7.47M
株価収益率:
-0.122
EPS:
-7.2117
ネットキャッシュフロー:
$-5.11M
1週間 パフォーマンス:
-19.99%
1か月 パフォーマンス:
-40.13%
6か月 パフォーマンス:
-87.88%
1年 パフォーマンス:
+70.89%
1日の値動き範囲:
$0.8703
$0.96
1週間の範囲:
$0.8703
$1.10
52週間の値動き範囲:
$0.226
$8.90
Scisparc Ltd Stock (SPRC) Company Profile
SPRC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
0.8801 | 4.05M | 1.31M | -7.47M | -5.11M | -7.2117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Scisparc Ltd (SPRC) 最新ニュース
SciSparc acquires MUSE system IP portfolio to enter GERD device market By Investing.com - Investing.com South Africa
SciSparc acquires MUSE system IP portfolio to enter GERD device market - Investing.com Nigeria
SciSparc Closes Acquisition of Xylo GERD Device IP, Moves to Immediate Commercialization - TipRanks
SciSparc Acquires Innovative GERD Device IP Portfolio from Xylo Technologies to Target Multi-Billion Dollar Market - Quiver Quantitative
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate ... - caledonianrecord.com
SciSparc targets $2.5B GERD device market with new MUSE patents - Stock Titan
Big Money Moves: Is Funko Inc part of any ETFJuly 2025 Chart Watch & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Wrap: Should you buy the dip on Rithm Acquisition Corp Debt Equity Composite UnitsWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
SciSparc receives Nasdaq notice over stockholders’ equity shortfall - MSN
Gainers Report: Is SciSparc Ltd backed by strong institutional buyingDollar Strength & AI Driven Price Predictions - baoquankhu1.vn
SPRC Stock Price, Forecast & Analysis | SCISPARC LTD (NASDAQ:SPRC) - Chartmill
Short Covering: What drives SciSparc Ltd.’s stock price2025 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Form 424B5 SciSparc Ltd. - StreetInsider
SciSparc Receives Nasdaq Notice Over Minimum Stockholders’ Equity Non-Compliance - The Globe and Mail
SciSparc to acquire MUSE endoscopic system patents from Xylo By Investing.com - Investing.com Nigeria
SciSparc to Acquire Endoscopic Device Patents Targeting $3B Market - Meyka
SciSparc Moves Into Endoscopy With Strategic Patent Deal - Benzinga
SciSparc Ltd. (SPRC) stock: dips nearly 12% as company unveils strategic MUSE™ endoscopic technology acquisition - parameter.io
SciSparc Faces Nasdaq Non-Compliance Challenge Over Stockholders’ Equity - StocksToTrade
SciSparc to acquire MUSE endoscopic system patents from Xylo - Investing.com
SciSparc Faces Nasdaq Noncompliance: Struggles Loom - StocksToTrade
SciSparc Launches $766,170 Registered Direct Share Offering - TipRanks
SciSparc Signs Agreement To Acquire Patent Portfolio For Endoscopic Technologies; Stock Soars - Nasdaq
SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal - marketscreener.com
SciSparc to Acquire Xylo GERD Device IP in Share-Based Deal, Targeting Global Endoscope Market - TipRanks
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity - The Manila Times
Whittier Daily News - FinancialContent
SciSparc receives Nasdaq non-compliance notice for stockholders’ equity By Investing.com - Investing.com Nigeria
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SciSparc receives Nasdaq non-compliance notice for stockholders’ equity - Investing.com
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance - The Manila Times
SciSparc Ltd. Receives Nasdaq Notification of Non-Compliance with Stockholders' Equity Requirement - Quiver Quantitative
Is SciSparc Ltd. stock oversold or undervaluedChart Signals & Low Drawdown Momentum Ideas - Улправда
Breakout Zone: How SciSparc Ltd stock benefits from global expansionJuly 2025 Intraday Action & Growth Focused Investment Plans - Bộ Nội Vụ
Published on: 2026-01-09 12:53:14 - Улправда
Why SciSparc Ltd. stock remains on watchlistsJuly 2025 WrapUp & Growth Focused Stock Reports - Улправда
Why SciSparc Ltd. stock is seen as undervalued2025 Market Sentiment & Growth-Oriented Investment Plans - Улправда
Neurothera Labs Announces Results of AGM - TheNewswire
VIX Spike: Why SciSparc Ltd. stock remains a top recommendationJuly 2025 Outlook & Free Fast Gain Swing Trade Alerts - Улправда
How strong is SciSparc Ltd. stock revenue growthMarket Sentiment Report & AI Enhanced Trading Alerts - Улправда
Why SciSparc Ltd. stock remains a top recommendation2025 Growth vs Value & Daily Chart Pattern Signals - Улправда
Can SciSparc Ltd. stock deliver strong Q4 earningsStop Loss Placement Tips & Small Investment Capital Tips - Улправда
SciSparc says Neurothera Labs granted patent by Israeli Patent Office - MSN
What drives SciSparc Ltd stock priceHigh Dividend Yield Stocks & Small Budget Capital Growth - Early Times
Libord Securities Limited Testing Reversal Zone on Weekly ChartMarket Sentiment Report & Outstanding Investment Returns - earlytimes.in
What analysts say about SciSparc Ltd stockStock Correlation Metrics & Daily Tips From Top Market Analysts - earlytimes.in
SciSparc Calls February 2026 Meeting to Approve New Deloitte Auditor and Executive Equity Awards - The Globe and Mail
SciSparc’s subsidiary NeuroThera receives patent in Israel for opioid tech By Investing.com - Investing.com Nigeria
SciSparc’s subsidiary NeuroThera receives patent in Israel for opioid tech - Investing.com India
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects - The Manila Times
Scisparc Ltd (SPRC) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):